Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 5Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Completed 19Recruiting 12Terminated 5Active not recruiting 5Withdrawn 3Unknown 3Suspended 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 4Metastatic Castration-resistant Prostate Cancer 1

Interventions

pembrolizumab 198Nivolumab 146Carboplatin 133Specimen Handling 130Magnetic Resonance Spectroscopy 116Cyclophosphamide 112Paclitaxel 106Biopsy 97Cisplatin 94Radiotherapy 89durvalumab 83Dexamethasone 80atezolizumab 73Ipilimumab 66Gemcitabine 60Doxorubicin 60Rituximab 59Lenalidomide 56Docetaxel 55olaparib 51Etoposide 51Bevacizumab 51Fluorouracil 49Capecitabine 49Radiation 47Oxaliplatin 47Radiosurgery 43Prednisone 43venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × abiraterone × Clear all
NCT04262154 2026-05-11

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
28 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT07553988 2026-04-28

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

R-Pharm

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
21 enrolled
Genitourinary

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
32 enrolled
Genitourinary

Prostatic Neoplasms

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
345 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡